GSK:LON
GSK plc
1 770,83 GBX
arrow_upward
+1,19%(+20,83) 1D
12 қаз., 18:17:16 GMT+1 · GBX
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GSK...
Open
1 755,00 GBX
High
1 771,00 GBX
Low
1 751,00 GBX
Mkt. cap
94,47 млрд
Avg. vol.
5,90 млн
Volume
3,15 млн
Dividend
3,84%
Quarterly dividend
17,00 GBX
Ex-dividend date
2026 ж. 13 там.
P/E ratio
15,01
52-wk high
2 282,00 GBX
52-wk low
1 592,00 GBX
EPS
1,18 GBX
Shares outstanding
4,32 млрд
No. of employees
67 мың
Open
1 755,00 GBX
High
1 771,00 GBX
Low
1 751,00 GBX
Mkt. cap
94,47 млрд
Avg. vol.
5,90 млн
Volume
3,15 млн
Dividend
3,84%
Quarterly dividend
17,00 GBX
Ex-dividend date
2026 ж. 13 там.
P/E ratio
15,01
52-wk high
2 282,00 GBX
52-wk low
1 592,00 GBX
EPS
1,18 GBX
Shares outstanding
4,32 млрд
No. of employees
67 мың
News stories
From web sources and news partners
Patch
·
5 сағат бұрын
Pharma Giant GSK To Expand In Upper Merion, Investing $800 Million
TipRanks
·
7 сағат бұрын
GSK Executives Reinvest Dividends in Routine Share Acquisitions
The Pharma Letter
·
11 сағат бұрын
Over $800 million investment from GSK to expand operations in Pennsylvania
Kalkine Media
·
12 сағат бұрын
Is GSK (LSE:GSK) Shares' Dip After The Nuvalent Deal A Pipeline Story In Focus?
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About GSK plc
CEOEmma Walmsley | Emma Walmsley
Employees66,8 мың
Founded2000 ж. 27 жел.
Headquarters-
SectorPharmaceutical industry
Websitegsk.com